Aadi Bioscience Bilan de santé

Santé financière contrôle des critères 6/6

Aadi Bioscience possède un total de capitaux propres de $68.9M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $85.7M et de $16.8M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$62.62m
Fonds propres	US$68.87m
Total du passif	US$16.83m
Total des actifs	US$85.70m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 3350 ( $77.3M ) dépassent ses passifs à court terme ( $15.8M ).

Passif à long terme: Les actifs à court terme de 3350 ( $77.3M ) dépassent ses passifs à long terme ( $1.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 3350 est sans dette.

Réduire la dette: 3350 n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 3350 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 3350 dispose d'une marge de trésorerie suffisante pour 1.1 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 38.2 % chaque année.

Aadi Bioscience Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Aadi Bioscience, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Aadi Bioscience, Inc. Approves Plan of Termination That Will Result in Workforce Reduction of 22 Employees, Representing Approximately 32% of the Workforce

Aadi Bioscience Provides PRECISION1 Trial Updates

Second quarter 2024 earnings released: US$0.54 loss per share (vs US$0.67 loss in 2Q 2023)

Aadi Bioscience, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Small Cap Comp Value Index

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

New minor risk - Profitability

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)

Aadi Bioscience, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings released: US$2.44 loss per share (vs US$2.69 loss in FY 2022)

Aadi Bioscience, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Aadi Bioscience, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Aadi Bioscience, Inc. Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Third quarter 2023 earnings released: US$0.60 loss per share (vs US$0.68 loss in 3Q 2022)

New minor risk - Market cap size

Aadi Bioscience, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$0.87 loss in 2Q 2022)

Aadi Bioscience, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: US$0.57 loss per share (vs US$0.66 loss in 1Q 2022)

High number of new directors

High number of new directors

High number of new directors

Aadi Bioscience, Inc. Announces Management Changes

High number of new directors

Third quarter 2022 earnings released: US$0.68 loss per share (vs US$9.17 loss in 3Q 2021)

Aadi Bioscience, Inc. Announces Executive Changes, Effective January 1, 2023

Aadi Bioscience, Inc. Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-Sirolimus at 34th EORTC-NCI-AACR Symposium

Now 21% undervalued

Second quarter 2022 earnings released: US$0.87 loss per share (vs US$0.22 loss in 2Q 2021)

Aadi Bioscience, Inc. Reports Impairment of Intangible Asset for the Second Quarter Ended June 30, 2022

Aadi Bioscience, Inc.(NasdaqCM:AADI) dropped from Russell Microcap Value Index

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications

Aadi Bioscience, Inc. Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Present at 2022 ASCO Annual Meeting

High number of new directors

First quarter 2022 earnings released: US$0.66 loss per share (vs US$0.71 loss in 1Q 2021)

Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders

Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services

High number of new directors

Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Aadi Bioscience, Inc. Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa

Interim Chief Financial Officer Lance Thibault has left the company

Aadi Bioscience, Inc. Announces FDA Approval of Its First Product Fyarro™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

No independent directors

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines